Literature DB >> 10682303

Brain phenylalanine concentration in the management of adults with phenylketonuria.

R A Moats1, R Koch, K Moseley, P Guldberg, F Guttler, R G Boles, M D Nelson.   

Abstract

Diagnosis by newborn screening and the implementation of a phenylalanine-restricted diet have resulted in normal neurological development in approximately 10,000 persons with phenylketonuria (PKU) in the United States. While it is accepted that a phenylalanine-restricted diet is necessary in childhood, the recommended concentration of phenylalanine in the blood varies. Clinicians now must make recommendations for adults with PKU who probably tolerate higher levels of phenylalanine than children. This factor, quality of life issues, the expense of the diet, and varying genetic and socioeconomic backgrounds, make the choice of dietary recommendations difficult. Molecular analysis of the mutations in PKU has provided insight but has not resulted in clear recommendations for phenylalanine concentration in the blood. Magnetic resonance imaging has provided the recognition that white-matter changes are present in PKU. However, owing to poor correlation of white-matter changes with clinical factors, analysis of white-matter changes has not proved useful. We hypothesize that measurement of brain phenylalanine directly will aid in clinical decision making. Twenty-one subjects with PKU had blood and brain phenylalanine measured simultaneously. Fifteen were randomly selected, 2 were examined for clinical reasons and 4 exceptional patients were chosen because they had maintained high IQs, despite having high historic blood concentrations and having been off the diet for at least 10 years. The correlation of blood and brain phenylalanine is in general poor. However, the four exceptional patients all had relatively low concentrations of phenylalanine in their brains compared to their blood. We suggest that their good clinical status, despite high historic blood levels, is due to their comparatively low brain levels of phenylalanine. We further suggest that measurement of brain phenylalanine concentration is useful in the management of PKU patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10682303     DOI: 10.1023/a:1005638627604

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  24 in total

1.  Treatment outcome of maternal phenylketonuria.

Authors:  R Koch; E Wenz; C Bauman; E G Friedman; C Azen; K Fishler; W Heiter
Journal:  Acta Paediatr Jpn       Date:  1988-08

Review 2.  Phenylketonuria.

Authors:  R Koch; E Wenz
Journal:  Annu Rev Nutr       Date:  1987       Impact factor: 11.848

3.  Intellectual, neurologic, and neuropsychologic outcome in untreated subjects with nonphenylketonuria hyperphenylalaninemia. German Collaborative Study on Phenylketonuria.

Authors:  J Weglage; K Ullrich; M Pietsch; B Fünders; F Güttler; E Harms
Journal:  Pediatr Res       Date:  1997-09       Impact factor: 3.756

4.  Human phenylalanine hydroxylase mutations and hyperphenylalaninemia phenotypes: a metanalysis of genotype-phenotype correlations.

Authors:  E Kayaalp; E Treacy; P J Waters; S Byck; P Nowacki; C R Scriver
Journal:  Am J Hum Genet       Date:  1997-12       Impact factor: 11.025

5.  Intelligence and quality of dietary treatment in phenylketonuria.

Authors:  I Smith; M G Beasley; A E Ades
Journal:  Arch Dis Child       Date:  1990-05       Impact factor: 3.791

6.  Effect of age at loss of dietary control on intellectual performance and behavior of children with phenylketonuria.

Authors:  N A Holtzman; R A Kronmal; W van Doorninck; C Azen; R Koch
Journal:  N Engl J Med       Date:  1986-03-06       Impact factor: 91.245

7.  Localized brain proton NMR spectroscopy in young adult phenylketonuria patients.

Authors:  K Johannik; P Van Hecke; B François; G Marchal; M H Smet; J Jaeken; L Breysem; G Wilms; A L Baert
Journal:  Magn Reson Med       Date:  1994-01       Impact factor: 4.668

Review 8.  White matter abnormalities in phenylketonuria: results of magnetic resonance measurements.

Authors:  K Ullrich; H Möller; J Weglage; G Schuierer; U Bick; A Ludolph; H Hahn-Ullrich; B Fünders; H G Koch
Journal:  Acta Paediatr Suppl       Date:  1994-12

9.  In-vivo NMR spectroscopy in patients with phenylketonuria: changes of cerebral phenylalanine levels under dietary treatment.

Authors:  H E Möller; P Vermathen; K Ullrich; J Weglage; H G Koch; P E Peters
Journal:  Neuropediatrics       Date:  1995-08       Impact factor: 1.947

10.  Identification and quantitation of phenylalanine in the brain of patients with phenylketonuria by means of localized in vivo 1H magnetic-resonance spectroscopy.

Authors:  R Kreis; J Pietz; J Penzien; N Herschkowitz; C Boesch
Journal:  J Magn Reson B       Date:  1995-06
View more
  9 in total

1.  Neuropsychological outcome of subjects participating in the PKU adult collaborative study: a preliminary review.

Authors:  V L Brumm; C Azen; R A Moats; A M Stern; C Broomand; M D Nelson; R Koch
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

2.  Large neutral amino acids in the treatment of phenylketonuria (PKU).

Authors:  R Matalon; K Michals-Matalon; G Bhatia; E Grechanina; P Novikov; J D McDonald; J Grady; S K Tyring; F Guttler
Journal:  J Inherit Metab Dis       Date:  2006-09-21       Impact factor: 4.982

3.  Phenylketonuria: brain phenylalanine concentrations relate inversely to cerebral protein synthesis.

Authors:  Martijn J de Groot; Paul E Sijens; Dirk-Jan Reijngoud; Anne M Paans; Francjan J van Spronsen
Journal:  J Cereb Blood Flow Metab       Date:  2014-10-29       Impact factor: 6.200

Review 4.  What we know that could influence future treatment of phenylketonuria.

Authors:  C N Sarkissian; A Gámez; C R Scriver
Journal:  J Inherit Metab Dis       Date:  2008-08-03       Impact factor: 4.982

5.  1H MR chemical shift imaging detection of phenylalanine in patients suffering from phenylketonuria (PKU).

Authors:  Paul E Sijens; Matthijs Oudkerk; Dirk-Jan Reijngoud; Klaas L Leenders; Harold W de Valk; Francjan J van Spronsen
Journal:  Eur Radiol       Date:  2004-08-03       Impact factor: 5.315

Review 6.  Large neutral amino acids supplementation in phenylketonuric patients.

Authors:  J C Rocha; F Martel
Journal:  J Inherit Metab Dis       Date:  2009-05-13       Impact factor: 4.982

7.  Phenylalanine can be detected in brain tissue of healthy subjects by 1H magnetic resonance spectroscopy.

Authors:  J Pietz; T Lutz; K Zwygart; G F Hoffmann; F Ebinger; C Boesch; R Kreis
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

8.  Adult cognitive outcomes in phenylketonuria: explaining causes of variability beyond average Phe levels.

Authors:  Cristina Romani; Filippo Manti; Francesca Nardecchia; Federica Valentini; Nicoletta Fallarino; Claudia Carducci; Sabrina De Leo; Anita MacDonald; Liana Palermo; Vincenzo Leuzzi
Journal:  Orphanet J Rare Dis       Date:  2019-11-28       Impact factor: 4.123

9.  Danger of high-protein dietary supplements to persons with hyperphenylalaninaemia.

Authors:  R Koch; K D Moseley; R Moats; S Yano; R Matalon; F Guttler
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.750

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.